Sellas Life Sciences Group company info

What does Sellas Life Sciences Group do?
Sellas Life Sciences (NASDAQ:SLS) is a biopharmaceutical company focused on the development of novel cancer immunotherapies. Its primary projects revolve around advancing treatments that target hematologic cancers and solid tumors, utilizing proprietary technology platforms to develop its pipeline. One of Sellas's flagship products includes GPS, a therapeutic vaccine aimed at multiple cancer types, demonstrating potential in improving patient outcomes by stimulating the immune system to attack cancer cells. The company's objective is to continue groundbreaking research and clinical trials to bring innovative therapies to market, offering new hope and options for patients battling cancer. With a commitment to exploiting the full potential of its technologies, Sellas is dedicated to making significant strides in oncology.
Sellas Life Sciences Group company media
Company Snapshot

Is Sellas Life Sciences Group a public or private company?

key
Ownership
Public

How many people does Sellas Life Sciences Group employ?

people
Employees
16

What sector is Sellas Life Sciences Group in?

pie chart
Sector
Health Care

Where is the head office for Sellas Life Sciences Group?

location pin
Head Office
New York, United States

What year was Sellas Life Sciences Group founded?

founded flag
Year Founded
2006
What does Sellas Life Sciences Group specialise in?
/Cancer Immunotherapies /Clinical Research /Biopharmaceuticals Development /Galena Biopharma /Healthcare Consulting /Cancer Vaccine

What are the products and/or services of Sellas Life Sciences Group?

Overview of Sellas Life Sciences Group offerings
GPS, a cancer immunotherapy targeting WT1-expressing cancers, representing a broad range of hematologic malignancies and solid tumors.
Nelipepimut-S, targeting HER2 3+ expressing breast cancer in combination with trastuzumab for a more effective treatment option.
A multifaceted clinical research program focusing on advanced melanoma treatments, exploring the efficacy and safety of novel immunotherapeutics.
Collaboration with leading pharmaceutical companies for the development of next-generation cancer vaccines aimed at multiple tumor antigens.
Investment in proprietary biotechnological platforms to enhance the precision and delivery of immunotherapies for hard-to-treat cancers.
Engagement in a partnership to explore the potential of mRNA technology for creating personalized cancer vaccines targeting specific mutations.

Who is in the executive team of Sellas Life Sciences Group?

Sellas Life Sciences Group leadership team
  • Dr. Angelos M. Stergiou M.D., ScD h.c.
    Dr. Angelos M. Stergiou M.D., ScD h.c.
    Founder, President, CEO & Director
  • Mr. John Thomas Burns CPA
    Mr. John Thomas Burns CPA
    Senior VP & CFO
  • Ms. Stacy E. Yeung
    Ms. Stacy E. Yeung
    VP, Associate General Counsel & Head of Compliance
  • Dr. Dragan  Cicic M.D., MBA
    Dr. Dragan Cicic M.D., MBA
    Senior Vice President of Clinical Development
  • Mr. Andrew  Elnatan
    Mr. Andrew Elnatan
    VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality